Novartis Paid $575 Million for a Chinese mRNA Drug. That Tells You Everything About Big Pharma’s R&D Crisis.
The question circulating in investment committees this week is not really about mRNA. It is about whether the largest pharmaceutical…
The question circulating in investment committees this week is not really about mRNA. It is about whether the largest pharmaceutical…
A note from our friends at MarketWise(ad) Editor’s Note: For nearly two decades, Whitney Tilson managed money for wealthy investors…
The Abogen deal is not a one-off bet. It signals China’s R&D edge.
October 3, 2026 Bonus Content: The COBOL Goldrush Is Minting New Winners, and Crushing IBM A note from our friends…
October 2, 2026 Frankfurt Has a Problem. Euro inflation just beat every forecast. December is no longer a formality. The…
A note from our friends at Base Camp Trading(ad) Dear Income Seeker, If you’re struggling to find high-probability income trades……
Layoffs at a four-year low and claims at 197k mean hiring can plateau without breaking — and that keeps the Fed’s next move unresolved heading into October 28.
A note from our friends at Weiss Ratings(ad) Dear Reader, Starting as soon as a few months from now, the…
Three sites, three schedules: Amkor in Arizona, SK hynix in Indiana, and Intel in New Mexico define the re-shoring sequence traders need to map.
The numbers were unambiguous. Micron posted adjusted earnings of $33.42 a share, well above the $31.16 forecast, on revenue of…